PharmaCyte BiotechPMCB
Market Cap: $15.9M
About: PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Employees: 2
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
0.67% more ownership
Funds ownership: 11.55% [Q1] → 12.22% (+0.67%) [Q2]
3% less funds holding
Funds holding: 29 [Q1] → 28 (-1) [Q2]
13% less capital invested
Capital invested by funds: $2.32M [Q1] → $2.02M (-$296K) [Q2]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for PMCB.